Roche‑Hansoh partnership: tracking deal completion and rollout

What happened

The National Medical Products Administration (NMPA) included Hansoh Pharmaceutical’s HS-20089, a B7-H4-targeted antibody-drug conjugate (ADC), as a breakthrough-therapy-designated drug for patients with platinum-resistant recurrent ovarian cancer 1. This designation follows the NMPA granting breakthrough status to another asset in the Hansoh-Roche portfolio, the B7-H3-targeted ADC HS-20093, for the treatment of non-small cell lung cancer (NSCLC) 1.

In the commercial sector, Hansoh secured its fifth marketing approval in China for Ameile (aumolertinib), authorizing the third-generation EGFR-TKI for use in a "targeted therapy plus chemotherapy" regimen 2. Concurrent with this domestic expansion, Hansoh entered into a licensing agreement with Glenmark, granting the firm exclusive multi-regional rights to aumolertinib 2. This agreement extends the drug's commercial footprint into new international territories beyond Hansoh’s existing core markets 2.

Why it matters

The breakthrough designations for HS-20089 and HS-20093 accelerate the regulatory pathway for the primary assets underpinning the $15 billion Roche-Hansoh partnership 1. By securing these statuses for platinum-resistant ovarian cancer and NSCLC, Hansoh establishes a prioritized clinical track for therapies that Roche is slated to commercialize in all territories outside of Mainland China, Hong Kong, Macau, and Taiwan 1.

The fifth approval for Ameile completes what the company describes as "full-course coverage" for the drug in China, integrating it into combination therapy standards 2. The Glenmark agreement shifts the commercial risk and distribution responsibility for aumolertinib in specific global regions to a third party, potentially increasing the royalty and milestone revenue stream for Hansoh as it manages the broader ADC rollout with Roche 2.

What's next

The NMPA’s breakthrough designation for HS-20089 and HS-20093 sets the stage for rolling submissions and potential priority review of future Biologics License Applications (BLAs) for these ADCs 1. A formal announcement regarding the specific territories covered under the Glenmark licensing deal would clarify the geographic boundaries of aumolertinib’s new commercial reach 2.

The commencement of global Phase Ib trials, which Hansoh is responsible for managing under the Roche agreement, will provide the next set of safety and efficacy data required for international regulatory filings. A decision from the NMPA regarding the pending BLA for HS-20093 in osteosarcoma, which received priority review in September 2026, would settle the drug's first authorized indication in China. The scheduled $110 million payment from Roche to Hansoh on the first anniversary of their agreement will confirm the partnership's progression into its second year of development.

What happened

Hansoh Pharmaceutical reported that its B7-H3-targeted antibody-drug conjugate (ADC), risvutatug rezetecan (HS-20093), met primary endpoints in two pivotal Phase 3 trials 2. In the ARTEMIS-008 trial, the drug achieved a statistically significant improvement in overall survival compared to topotecan for patients with small cell lung cancer 2. The registrational ARTEMIS-011 trial also met its primary endpoint, demonstrating improved progression-free survival (PFS) as assessed by an independent review committee for patients with osteosarcoma 2. These clinical results follow the U.S. Food and Drug Administration (FDA) granting Breakthrough Therapy Designation to HS-20093 in January 2025 for adult patients with relapsed or refractory osteosarcoma who progressed on at least two prior therapies 1.

In a separate expansion of its immunology portfolio, Hansoh entered a licensing collaboration and strategic investment agreement with Avere for HS-20118 2. The asset is an oral peptide interleukin-23 (IL-23) receptor antagonist currently supported by Phase 1b data for the treatment of psoriasis 2.

For the full year ended December 31, 2025, Hansoh recorded total revenue of RMB15,028 million, a 22.6% increase over the previous year 1. Sales from innovative medicines and collaborative products rose 30.4% to RMB12,354 million, representing 82.2% of the company's total revenue 1. The company increased its R&D expenditure by 24.3% to RMB3,358 million during the same period 1. Net profit for 2025 reached RMB5,555 million, a 27.1% year-over-year increase 1.

Why it matters

The Phase 3 success of risvutatug rezetecan provides the clinical validation required for the regulatory filings currently under review by the NMPA. Because Roche holds the rights for development and commercialization in all territories outside of Mainland China, Hong Kong, Macau, and Taiwan, these results establish the efficacy profile necessary for global regulatory submissions. The statistically significant improvement in overall survival in small cell lung cancer and PFS in osteosarcoma addresses high-unmet-need oncology segments where existing treatments like topotecan have limited efficacy 2.

Hansoh’s financial performance in 2025 indicates a structural shift toward high-margin innovative therapies, which now account for more than 80% of its revenue 1. The 30.4% growth in this segment suggests that the company's transition from a generic-focused manufacturer to an innovation-driven enterprise is yielding higher returns, supporting a 26.4% increase in basic earnings per share to RMB0.93 1. The strategic investment in the oral IL-23 antagonist HS-20118 positions the company to compete in the immunology market with a potentially more convenient oral alternative to injectable biologics 2.

What's next

The NMPA is currently reviewing the Biologics License Applications for HS-20093 in small cell lung cancer and osteosarcoma. Approval by the NMPA would allow Hansoh to begin commercial sales of the ADC in China.

Following the FDA's Breakthrough Therapy Designation, the submission of a Biologics License Application to the FDA would be the next step for U.S. market entry. Avere and Hansoh intend to rapidly develop HS-20118 as a treatment for psoriasis following the recent strategic investment 2. Hansoh’s board has recommended a final dividend of HK$20.00 cents per share for the 2025 fiscal year, which requires approval at the upcoming Annual General Meeting to settle the full-year payout of HK$43.16 cents per share 1.

What happened — the development in detail

The U.S. Food and Drug Administration (FDA) granted Priority Review to Roche’s supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) on July 15, 2026 1. The application seeks approval for the treatment of adults with primary membranous nephropathy (pMN), a chronic autoimmune kidney disease 1. This regulatory status follows the FDA’s April 2026 decision to grant the drug Breakthrough Therapy Designation for the same indication 1.

The sBLA submission is supported by data from the Phase III MAJESTY study, which compared Gazyva to the immunosuppressive therapy tacrolimus 1. In the trial, 36.9% of adults treated with Gazyva achieved complete remission at two years (104 weeks), compared to 5.7% of those treated with tacrolimus 1. This represents an adjusted difference of 31.1% (p<0.001) 1. Secondary endpoints showed Gazyva was superior in achieving overall remission at week 104 and complete remission at week 76 1. Roche reported that safety results were consistent with the drug's established profile, with no new safety signals identified 1.

This filing marks the second priority review the FDA has granted for Gazyva in 2026, following a May 2026 application for the treatment of idiopathic nephrotic syndrome 1. Roche is also submitting the MAJESTY trial data to the European Medicines Agency (EMA) and other global health authorities 1.

Why it matters — the consequences for the people exposed to this outcome

If authorized, Gazyva would become the first FDA-approved therapy for primary membranous nephropathy 1. Currently, there are no therapies for pMN approved by either the FDA or the EMA 1. The disease causes potentially irreversible kidney damage, and up to 30% of untreated patients progress to kidney failure within 10 years 1.

The clinical objective in pMN is achieving complete remission to maintain kidney function and delay fatal complications 1. The MAJESTY trial results indicate that Gazyva, which targets tissue-resident B cells, may help a significantly higher proportion of patients reach this goal compared to current immunosuppressive options like tacrolimus 1.

For Roche, the pMN application is part of a broader expansion of Gazyva’s indications beyond its existing approvals for active lupus nephritis in the U.S. and EU 1. The drug is currently being evaluated in several other immune-mediated conditions, including systemic lupus erythematosus and idiopathic nephrotic syndrome 1.

What's next — the concrete next events

The FDA is expected to issue a decision on the sBLA for primary membranous nephropathy by November 2026 1. A positive decision would trigger the commencement of commercial sales for this indication in the United States.

Parallel to the U.S. process, the EMA will review the MAJESTY data to determine marketing authorization in the European Union 1. A recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) would be the next formal step in the European regulatory timeline. Roche is also continuing the Phase II POSTERITY study, which evaluates the use of Gazyva in children and adolescents with lupus nephritis 1.

What happened

The U.S. Food and Drug Administration accepted Roche’s New Drug Application for fenebrutinib under priority review on September 30, 2026 2. The application seeks approval for the investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor to treat both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) 2. The submission is supported by data from three Phase III trials: FENhance 1 and 2 for RMS, and FENtrepid for PPMS 2.

In the FENhance 1 and 2 studies, fenebrutinib reduced the annualized relapse rate by 51.1% and 58.5% respectively when compared to teriflunomide over a 96-week period 2. Roche reported these results as the lowest relapse rates observed in Phase III MS studies, equating to approximately one relapse every 17 years 2. In the FENtrepid study, fenebrutinib met its primary endpoint of non-inferiority against Ocrevus, which is currently the only approved medicine for PPMS 2. The drug showed a 12% numerical reduction in the risk of disability progression compared to Ocrevus, with the performance curves separating at 24 weeks 2.

Why it matters

Fenebrutinib is the first investigational medicine in more than a decade to demonstrate a numerical benefit in slowing disability progression in a Phase III PPMS trial 2. If the FDA grants approval, the drug would become the first BTK inhibitor and the first high-efficacy oral treatment available for both RMS and PPMS 2. This would provide a new therapeutic option for the nearly 1 million Americans living with MS, particularly the one-third of patients currently receiving lower-efficacy treatments 2.

The drug is designed to cross the blood-brain barrier to target chronic brain inflammation, which is believed to drive disability progression, alongside the acute inflammation that causes relapses 2. By offering an oral alternative to existing high-efficacy therapies like Ocrevus, Roche aims to provide patients with greater flexibility and choice in managing long-term disease activity 2. The European Medicines Agency also maintains an active file on Ocrevus regarding variations to its marketing authorization, reflecting the ongoing regulatory focus on this therapeutic class 1.

What's next

The FDA’s priority review status for the fenebrutinib application indicates an expedited assessment timeline compared to standard reviews. A decision from the agency would determine if fenebrutinib can enter the U.S. market as the first oral high-efficacy therapy for the full MS spectrum.

Future clinical data releases or regulatory filings in other jurisdictions, such as the European Union, would clarify the global commercial trajectory for the drug. The commencement of commercial sales in the U.S. would follow an affirmative FDA decision. Continued monitoring of the Ocrevus marketing authorization variations by the European Medicines Agency will determine if additional updates to the current standard of care are implemented 1.

What happened

The National Medical Products Administration (NMPA) of China issued a Notice of Approval for Drug Clinical Trials to Hansoh Pharmaceutical on September 11, 2026, for HS-20197 1. The drug is an independently developed Class 1 new drug for injection 1. Hansoh intends to conduct clinical trials for the therapy in patients with advanced solid tumors 1.

Roche expanded its metabolic pipeline on October 13, 2026, by signing a licensing agreement with Rona Therapeutics for an experimental RNA interference (RNAi) medicine 2. Under the terms of the pact, Roche paid $100 million upfront to gain full ownership of the drug, which targets the ALK7 protein 2. The agreement includes potential milestone payments that could bring the total deal value to just over $1 billion, in addition to sales royalties for Rona 2. The ALK7-targeting agent is designed to lower levels of visceral fat by silencing a cell surface receptor expressed in fat tissue that regulates lipid metabolism 2. This transaction marks Roche’s fifth deal with a China-based drugmaker since late August 2026 and its tenth since the start of 2025 2.

Why it matters

The approval for HS-20197 allows Hansoh to move an internally developed asset into the clinical phase, targeting the oncology market for advanced solid tumors 1. This development follows the company's broader strategy of advancing its own technology platforms alongside its multi-billion dollar partnership with Roche.

Roche’s acquisition of the Rona Therapeutics asset positions the company in the competitive field of visceral fat reduction 2. The ALK7 target is a distinct mechanism from the "incretin" drugs currently marketed by Eli Lilly and Novo Nordisk 2. By targeting adipose tissue biology directly, Roche aims to address the quality and durability of weight loss, potentially offering a therapy that can be combined with existing incretin treatments 2. The $1 billion commitment reflects the market value of RNAi-based metabolic therapies, as Roche joins GSK, Alnylam Pharmaceuticals, and Arrowhead Pharmaceuticals in developing prospects for this specific pathway 2. The deal also reinforces Roche's reliance on Chinese innovation, as it has signed more licensing deals with China-based firms than any of its pharmaceutical peers since 2025 2.

What's next

Hansoh is scheduled to begin clinical trials for HS-20197 in advanced solid tumors following the NMPA approval 1. The commencement of these trials will provide the first data on the safety and efficacy of the Class 1 injection.

For the Roche-Rona partnership, the therapy must now progress through development, regulatory, and commercial milestones to trigger the remaining $900 million in potential payments 2. Roche will integrate the ALK7 program into its existing obesity pipeline, which currently includes five other experimental medicines 2. Results from Phase 1 testing of similar ALK7-targeting agents by competitors Alnylam and Arrowhead will provide the first benchmarks for the efficacy of this mechanism in humans 2. A statement from Roche regarding the start of Phase 1 trials for the Rona asset would confirm the drug's entry into clinical development.